dc.contributor.author | Godman, Brian![]() |
|
dc.contributor.author | McCabe, Holly![]() |
|
dc.contributor.author | Leong, Trudy D.![]() |
|
dc.contributor.author | Mueller, Debjan![]() |
|
dc.contributor.author | Martin, Antony P.![]() |
|
dc.contributor.author | Hoxha, Iris![]() |
|
dc.contributor.author | Mwita, Julius C.![]() |
|
dc.contributor.author | Rwegerera, Godfrey Mutashambara![]() |
|
dc.contributor.author | Massele, Amos![]() |
|
dc.contributor.author | De Oliveira Costa, Juliana![]() |
|
dc.contributor.author | Do Nascimento, Renata Cristina Rezende Macedo![]() |
|
dc.contributor.author | De Lemos, Livia Lovato Pires![]() |
|
dc.contributor.author | Tachkov, Konstantin![]() |
|
dc.contributor.author | Milushewa, Petya![]() |
|
dc.contributor.author | Patrick, Okwen![]() |
|
dc.contributor.author | Niba, Loveline Lum![]() |
|
dc.contributor.author | Laius, Ott![]() |
|
dc.contributor.author | Sefah, Israel Abebrese![]() |
|
dc.contributor.author | Abdulsalim, Suha![]() |
|
dc.contributor.author | Soleymani, Fatemeh![]() |
|
dc.contributor.author | Guantai, Anastasia N.![]() |
|
dc.contributor.author | Achieng, Loice![]() |
|
dc.contributor.author | Oluka, Margaret![]() |
|
dc.contributor.author | Jakupi, Arianit![]() |
|
dc.contributor.author | Logviss, Konstantins![]() |
|
dc.contributor.author | Hassali, Mohamed Azmi![]() |
|
dc.contributor.author | Kibuule, Dan![]() |
|
dc.contributor.author | Kalemeera, Francis![]() |
|
dc.contributor.author | Mubita, Mwangana![]() |
|
dc.contributor.author | Fadare, Joseph![]() |
|
dc.contributor.author | Ogunleye, Olayinka O.![]() |
|
dc.contributor.author | Saleem, Zikria![]() |
|
dc.contributor.author | Hussain, Shazhad![]() |
|
dc.contributor.author | Bochenek, Tomasz![]() |
|
dc.contributor.author | Mardare, Ileana![]() |
|
dc.contributor.author | Alrasheedy, Alian A.![]() |
|
dc.contributor.author | Furst, Jurij![]() |
|
dc.contributor.author | Tomek, Dominik![]() |
|
dc.contributor.author | Markovic-Pekovic, Vanda![]() |
|
dc.contributor.author | Rampamba, Enos M.![]() |
|
dc.contributor.author | Alfadl, Abubakr![]() |
|
dc.contributor.author | Amu, Adefolarin A.![]() |
|
dc.contributor.author | Matsebula, Zinhle![]() |
|
dc.contributor.author | Phuong, Thuy Nguyen Thi![]() |
|
dc.contributor.author | Thanh, Binh Nguyen![]() |
|
dc.contributor.author | Kalungia, Aubrey Chichonyi![]() |
|
dc.contributor.author | Zaranyika, Trust![]() |
|
dc.contributor.author | Masuka, Nyasha![]() |
|
dc.contributor.author | Olaru, Ioana D.![]() |
|
dc.contributor.author | Wale, Janney![]() |
|
dc.contributor.author | Hill, Ruaraidh![]() |
|
dc.contributor.author | Kurdi, Amanj![]() |
|
dc.contributor.author | Timoney, Angela![]() |
|
dc.contributor.author | Campbell, Stephen![]() |
|
dc.contributor.author | Meyer, Johanna Catharina![]() |
|
dc.date.accessioned | 2020-09-29T07:56:23Z | |
dc.date.available | 2020-09-29T07:56:23Z | |
dc.date.issued | 2020 | |
dc.description.abstract | INTRODUCTION : There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. AREAS COVERED : Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. EXPERT COMMENTARY : FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed. | en_ZA |
dc.description.department | School of Health Systems and Public Health (SHSPH) | en_ZA |
dc.description.librarian | hj2020 | en_ZA |
dc.description.uri | https://www.tandfonline.com/loi/ierp20 | en_ZA |
dc.identifier.citation | Brian Godman , Holly McCabe , Trudy D Leong , Debjani Mueller , AntonyP. Martin , Iris Hoxha , Julius C. Mwita , Godfrey Mutashambara Rwegerera , Amos Massele ,Juliana de Oliveira Costa , Renata Cristina Rezende Macedo do Nascimento , Livia Lovato Pires deLemos , Konstantin Tachkov , Petya Milushewa , Okwen Patrick , Loveline Lum Niba , Ott Laius ,Israel Sefah , Suhaj Abdulsalim , Fatemeh Soleymani , Anastasia N Guantai , Loice Achieng , Margaret Oluka , Arianit Jakupi , Konstantīns Logviss , Mohamed Azmi Hassali , Dan Kibuule ,Francis Kalemeera , Mwangana Mubita , Joseph Fadare , Olayinka O. Ogunleye , Zikria Saleem ,Shazhad Hussain , Tomasz Bochenek , Ileana Mardare , Alian A. Alrasheedy , Jurij Furst , DominikTomek , Vanda Markovic-Pekovic , Enos M. Rampamba , Abubakr Alfadl , Adefolarin A Amu ,Zinhle Matsebula , Thuy Nguyen Thi Phuong , Binh Nguyen Thanh , Aubrey Chichonyi Kalungia ,Trust Zaranyika , Nyasha Masuka , Ioana D. Olaru , Janney Wale , Ruaraidh Hill , Amanj Kurdi ,Angela Timoney , Stephen Campbell & Johanna C. Meyer (2020) Fixed dose drug combinations –are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Review of Pharmacoeconomics & Outcomes Research, 20:1, 1-26, DOI:10.1080/14737167.2020.1734456. | en_ZA |
dc.identifier.issn | 1473-7167 (print) | |
dc.identifier.issn | 1744-8379 (online) | |
dc.identifier.other | 10.1080/14737167.2020.1734456 | |
dc.identifier.uri | http://hdl.handle.net/2263/76258 | |
dc.language.iso | en | en_ZA |
dc.publisher | Taylor and Francis | en_ZA |
dc.rights | © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License. | en_ZA |
dc.subject | Fixed dose combination (FDC) | en_ZA |
dc.subject | Lower-middle-income countries (LMIC) | en_ZA |
dc.subject | Pharmacoeconomics | en_ZA |
dc.subject | Adherence | en_ZA |
dc.subject | Medicines | en_ZA |
dc.subject | Non-communicable diseases (NCDs) | en_ZA |
dc.subject | Infectious diseases | en_ZA |
dc.title | Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries | en_ZA |
dc.type | Article | en_ZA |